{"entity":{"id":"nct07549399","kind":"trial","name":"SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC","aka":["CRITII"],"tldr":"A phase 3 trial of cetuximab and bevacizumab (glioblastoma use) in colorectal cancer, run by Sixth Affiliated Hospital, Sun Yat-sen University, now recruiting.","summary":"SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC is a phase 3, randomised interventional study registered as NCT07549399 by Sixth Affiliated Hospital, Sun Yat-sen University, with a registry enrolment figure of 204 participants, started 2026-05-20 and due to reach its primary completion in 2029-04-30. Interventions recorded: Short-Course Radiotherapy; PD-1 monoclonal antibody; mFOLFOX6 regimen; Cetuximab; Bevacizumab; Surgical resection. Conditions listed: Rectal Adenocarcinoma; High-Risk Cancer; MSS. Primary outcome: 3 years DFS Rate. Colorectal eligibility wording from the registry: \"Histologically or cytologically confirmed pMMR/MSS rectal adenocarcinoma; all other histological types are excluded\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07549399","url":"https://clinicaltrials.gov/study/NCT07549399"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer"],"sections":[],"technologies":["imrt-igrt","monoclonal-antibody"],"targets":[],"drugs":["cetuximab","bevacizumab-glioma"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07549399","phase":"3","setting":"Short-Course Radiotherapy Combined With mFOLFOX6, PD-1 Antibody and Cetuximab (for RAS/BRAF Wild-Type)/Bevacizumab (for RAS/BRAF Mutant) in High-Risk pMMR/MSS Rectal Adenocarcinoma: a Phase III Randomized Controlled Trial","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","enrolled":204,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07549399/","neighbours":{"cancer":[{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}